ANIX Anixa Biosciences Inc

Nasdaq anixa.com


$ 4.18 $ -0.30 (-6.82 %)    

Friday, 17-Oct-2025 18:25:30 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 4.1
$ 4.34
$ 4.03 x 1,000
$ 4.50 x 150
$ 4.09 - $ 4.35
$ 2.07 - $ 4.98
204,622
na
134.96M
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 09-10-2025 07-31-2025 10-Q
2 05-28-2025 04-30-2025 10-Q
3 03-11-2025 01-31-2025 10-Q
4 01-10-2025 10-31-2024 10-K
5 09-06-2024 07-31-2024 10-Q
6 06-04-2024 04-30-2024 10-Q
7 03-12-2024 01-31-2024 10-Q
8 01-16-2024 10-31-2023 10-K
9 09-06-2023 07-31-2023 10-Q
10 06-14-2023 04-30-2023 10-Q
11 03-17-2023 01-31-2023 10-Q
12 01-04-2023 10-31-2022 10-K
13 09-09-2022 07-31-2022 10-Q
14 06-10-2022 04-30-2022 10-Q
15 03-11-2022 01-31-2022 10-Q
16 01-04-2022 10-31-2021 10-K
17 09-01-2021 07-31-2021 10-Q
18 06-10-2021 04-30-2021 10-Q
19 03-11-2021 01-31-2021 10-Q
20 01-07-2021 10-31-2020 10-K
21 09-08-2020 07-31-2020 10-Q
22 06-09-2020 04-30-2020 10-Q
23 03-09-2020 01-31-2020 10-Q
24 01-09-2020 10-31-2019 10-K
25 09-06-2019 07-31-2019 10-Q
26 06-12-2019 04-30-2019 10-Q
27 03-13-2019 01-31-2019 10-Q
28 01-11-2019 10-31-2018 10-K
29 09-07-2018 07-31-2018 10-Q
30 06-11-2018 04-30-2018 10-Q
31 03-09-2018 12-01-2017 10-Q
32 01-09-2018 10-31-2017 10-K
33 09-08-2017 07-31-2017 10-Q
34 05-26-2017 04-30-2017 10-Q
35 03-16-2017 01-31-2017 10-Q
36 12-07-2016 10-31-2016 10-K
37 08-19-2016 07-31-2016 10-Q
38 05-20-2016 04-30-2016 10-Q
39 02-19-2016 01-31-2016 10-Q
40 12-23-2015 10-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 d-boral-capital-maintains-buy-on-anixa-biosciences-maintains-10-price-target

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.

 anixa-biosciences-completes-the-final-patient-visit-in-its-phase-1-breast-cancer-vaccine-clinical-trial

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatm...

 d-boral-capital-maintains-buy-on-anixa-biosciences-maintains-10-price-target

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.

 anixa-to-present-phase-1-breast-cancer-vaccine-data-at-2025-san-antonio-breast-cancer-symposium

Phase 1 Data Highlights Potential of First-in-Class Vaccine to Transform Breast Cancer Treatment and PreventionComprehensive Re...

 hc-wainwright--co-reiterates-buy-on-anixa-biosciences-maintains-7-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $7 price target.

 anixa-biosciences-files-for-mixed-shelf-of-up-to-200m

- SEC Filing

 anixa-biosciences-q3-eps-007-beats-009-estimate

Anixa Biosciences (NASDAQ:ANIX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0...

 d-boral-capital-maintains-buy-on-anixa-biosciences-maintains-10-price-target

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.

 anixa-biosciences-completes-dosing-of-fourth-cohort-in-ongoing-phase-1-clinical-trial-evaluating-fshr-targeted-car-tcer-t-therapy-for-recurrent-ovarian-cancer

Continue to observe a positive safety profile—no dose limiting toxicities, cytokinerelease syndrome or immune effector cell-ass...

 anixa-biosciences-receives-cnipa-notice-of-allowance-for-breast-cancer-vaccine-patent-expanding-global-ip-portfolio

Notice of Allowance marks first Chinese patent to be issued on Anixa Breast Cancer VaccineExpands global intellectual property ...

 d-boral-capital-maintains-buy-on-anixa-biosciences-maintains-10-price-target

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.

 anixa-biosciences-announces-second-patient-in-fourth-dose-cohort-treated-in-ongoing-phase-1-clinical-trial-evaluating-chimeric-antigen-receptor-t-cell-therapy-for-recurrent-ovarian-cancer

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatm...

 anixa-biosciences-secures-new-patent-extending-solid-tumor-car-t-platform-protection-to-2045

Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045SAN JOSE, Calif., Aug. 12, 2025 /PRNews...

Core News & Articles

New Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, a...

 d-boral-capital-maintains-buy-on-anixa-biosciences-maintains-10-price-target

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:ANIX) with a Buy and maintains $10 price target.

 anixa-biosciences-advances-breast-cancer-vaccine-to-phase-2-initiates-ind-transfer-from-cleveland-clinic-following-phase-1-results

Progress Follows Positive Immune Response Observed in Phase 1 StudySAN JOSE, Calif., Aug. 4, 2025 /PRNewswire/ -- Anixa Bioscie...

 anixa-biosciences-announces-it-has-been-awarded-a-new-us-patent-extending-its-breast-cancer-vaccine-ip-protection-into-the-2040s

Patent Expands Immunogenic Coverage of α-Lactalbumin-Based Vaccine PlatformTechnology Addresses Substantial Unmet Need in Preve...

 anixa-biosciences-announces-it-has-initiated-dosing-in-fourth-cohort-in-its-ovarian-cancer-car-t-clinical-trial

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatm...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION